Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era. Kluge, R. et al. All articles published by MDPI are made immediately available worldwide under an open access license. Journal of Personalized Medicine. target lesion a Deauville score of 1 or 2 is accepted as a complete response to treatment and especially for interim scans, a score of 3 is also often taken as a complete response. Imaging 41, 13011308. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Ganeshan et al. Would you like email updates of new search results? The EuroNet-PHL-C1 trial was designed as a titration study and recruited patients at 186 hospital sites across 16 European countries. Use the Previous and Next buttons to navigate the slides or the slide controller buttons at the end to navigate through each slide. ; Zucca, E.; Lister, T.A. Required fields are marked *. Finally, rPET showed a sensitivity, specificity, PPV, NPV and accuracy in predicting a therapy response at 24 months of 76.1%, 100%, 100%, 35.3% and 78.8%, respectively, with a cut-off of 1.31 and an AUC of 0.913 (CI, Hodgkin lymphoma is the third-most-common childhood malignancy. WebRisk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphomanasal typea multicentreretrospective analysis [J]. 1996-2023 MDPI (Basel, Switzerland) unless otherwise stated. You are accessing a machine-readable page. The https:// ensures that you are connecting to the doi: 10.1016/S2352-3026(21)00102-2. You are using a browser version with limited support for CSS. Results: For 202 patients treated with chemotherapy with or without radiation therapy, the 5-year FFP was 89% (95% confidence interval 85%-93%). https://doi.org/10.1158/0008-5472.CAN-17-0339 (2017). It is also an expensive and time-consuming procedure, resulting in a high radiation dose for the often young patients9. Do Deauville scores improve the clinical utility of end-of-therapy FDG PET scans for pediatric Hodgkin lymphoma? Epub 2016 Mar 2. 20, 641649. Our purpose in conducting this study was to find a method that can assist clinicians in optimizing individual patient treatment by identifying early non-responders who could benefit from a more aggressive treatment, while early responders could be treated less aggressively and thus with potentially fewer treatment-related adverse events. R package version 4.71. https://doi.org/10.1200/JCO.2013.54.8800 (2014). We use cookies on our website to ensure you get the best experience. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Open Access funding enabled and organized by Projekt DEAL. The National Comprehensive Cancer Network (NCCN) recommends avoiding certain chemotherapeutic agents in patients older than 60 years. Informed consent was obtained from all subjects involved in the study. A slight misalignment is also visible in (b), which we corrected when we copied the segmentation mask from the CT to the PET images. Further classification of distinct lymphoma subtypes is beyond the scope of this article; however, they are ultimately each defined by morphology, immunopheno-type, genetic, molecular, and clinical features.1,3 This article will focus on the types of lymphoma traditionally classified as non-Hodgkin or Hodgkin. https://doi.org/10.1080/10428194.2020.1786555 (2020). suggested a link between the non-contrast-enhanced CT-derived texture parameter kurtosis and shorter progression-free survival of lymphoma patients in an 18F-FDG-PET/CT study, including patients with Hodgkin lymphoma and aggressive Non-Hodgkin lymphoma14. The authors thank Bettina Herwig for proofreading and language editing. (This article belongs to the Special Issue, Tailoring treatment in patients with Hodgkin lymphoma (HL) is paramount to maximize outcomes while avoiding unnecessary toxicity. 3: 445. CT radiomics to predict Deauville score 4 positive and negative Hodgkin lymphoma manifestations, https://doi.org/10.1038/s41598-022-24227-0. Methods 188, 2029. The statistical analysis involved several steps. Meignan, M., Gallamini, A., Meignan, M., Gallamini, A. Robin, X. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma [J]. Med. Please enable it to take advantage of the complete set of features! BMC Bioinf. Rep. 12, 10192. https://doi.org/10.1038/s41598-022-13967-8 (2022). Korula A, Fouzia NA, Devasia A, Kulkarni U, Abraham A, Srivastava A. Bair SM, Svoboda J. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging. Ethical review and approval were waived for this study due to its observational and retrospective nature. Deauville score versus ratio Deauville score in the interpretation of interim 18F-FDG PET-CT and in prediction of outcome in children with FDG-avid extra-nodal lymphomas. Boellaard, R. Standards for PET image acquisition and quantitative data analysis. In another study, Knogler et al. The datasets generated and/or analyzed during the current study are not publicly available due to an IRB decision which was made in the interest of ensuring patient confidentiality but are available from the corresponding author on reasonable request. Giesel, F. L. et al. WebNeurolymphomatosis: an uncommon manifestation of lymphoma detection and therapeutic monitoring through 18F-fluorodeoxyglucose positron-emission tomography and computed tomography imaging. Data were analyzed using the SPSS software package, version 20.0 (. Accessibility https://doi.org/10.1016/j.ymeth.2020.05.022 (2021). Subsequent chemotherapy toxicities include neuropathy, cardiotoxicity, and secondary cancers such as lung and breast, and should be considered in the shared decision-making process to select a treatment regimen. 18F-Fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) is the standard diagnostic test for end-of-treatment assessment in Hodgkin lymphoma1, which accounts for 10% of all diagnosed lymphomas2. Barrington, S.F. Treatment of lymphoma consists of chemotherapy alone or in combination with radiotherapy.24 Radiotherapy alone is not recommended.25 Toxicity from radiotherapy can lead to serious long-term complications such as secondary cancers in the irradiated area, including breast or lung cancers.25 Additionally, patients receiving chemotherapy can subsequently develop breast or lung cancers, melanoma, or acute myeloid leukemia.26,27 Patients who are older than 60 years at diagnosis have worse outcomes, regardless of the staging. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. The .gov means its official. To achieve reproducible results, we determined the final DS using the qPET approach23. government site. Patients with lymphoma should have intensive follow-up surveillance for the first two years following remission. In particular, international guidelines recommend using the Deauville criteria to assign patients a score of 1 through 5, indicating their response to treatment as Patient information: See related handout on lymphoma, written by the authors of this article. Cancers (Basel) 13. https://doi.org/10.3390/cancers13143634 (2021). 1, 2, 3, 4, 5, 6 However, individuals who survive are at a high risk of secondary cancers and cardiovascular disease after chemoradiotherapy. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). 2002;359(9323):2065-2071. Marani C, Raiola AM, Morbelli S, Dominietto A, Ferrarazzo G, Avenoso D, Giannoni L, Varaldo R, Gualandi F, Grazia D, Lamparelli T, Bregante S, Van Lint MT, Ibatici A, Bovis F, Lemoli RM, Gobbi M, Bacigalupo A, Angelucci E. Biol Blood Marrow Transplant. Overall, 26 initial and 49 interim examinations were included. Chih-Yang Hsu, Mike Doubrovin, John T. Lucas Jr. Scientific Reports Rep. 10, 11649. https://doi.org/10.1038/s41598-020-68310-w (2020). Details of the patients are summarized in Table 1. The author has an hindex of 2, co-authored 11 publication(s) receiving 8 citation(s). WebRisk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphomanasal typea multicentreretrospective analysis [J]. https://doi.org/10.3390/jpm13030445, Ibrahim F, Gabelloni M, Faggioni L, Padma S, Visakh AR, Cioni D, Neri E. Are Semiquantitative Methods Superior to Deauville Scoring in the Monitoring Therapy Response for Pediatric Hodgkin Lymphoma? Leuk Lymphoma 2009;50:1257-60. Hosmer Jr, D. W., Lemeshow, S. & Sturdivant, R. X. pROC: An open-source package for R and S+ to analyze and compare ROC curves. ), or their login data. Our results should be verified in larger, more consistent patient populations examined on CT scanners from additional vendors to affirm median as a robust feature across scanners and should be validated externally according to Shahzadi44 supporting clinical applicability. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979). ; et al. Psychol. PubMed methods, instructions or products referred to in the content. Lymphoma 50, 12571260. PopUp = window.open( location,'RightsLink','location=no,toolbar=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,width=650,height=550'); }, Source of Support: None, Conflict of Interest: None. Author to whom correspondence should be addressed. Semin. An official website of the United States government. ; supervision, S.N.N. A DS of 3 or less is considered an adequate, and a DS of 4 or greater is considered an inadequate treatment response. https://doi.org/10.5152/dir.2015.15220 (2016). High rMTV41% (rMTVhigh , 4.4 cm3 ) predicted significantly poorer EFS in patients with DS 4-5 (HR, 3.70; p = .014). Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM. Sci Rep 8, 13047. https://doi.org/10.1038/s41598-018-31509-z (2018). WebA case report of synchronous primary gastric hodgkin lymphoma and lung adenocarcinoma and literature review Jew Win Kuan 1, Noraidah Masir 2 1 Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kota Samarahan, Malaysia 2 Prince Court Medical Centre, Pantai Premier Pathology, Kuala PET scan followed after a median uptake time of 68min (IQR, 63.576.5min). Internet Explorer). ; Zucca, E.; Fisher, R.I.; Trotman, J.; et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Long-term cause specific mortality of patients treated for Hodgkins disease. ; writingoriginal draft preparation, F.I. Harell, F. Jr. Hmisc: Harrell Miscellaneous. We included a total of 75 PET/CT datasets acquired in 43 patients. When using the DS method, 31 (71.1%) patients were classified as responders (DS 1, 2 and 3) at interim PET-CT, whereas 47 (90.4%) were classified as responders at post-therapy PET-CT. No patients had a DS of 5 at either the interim or post-therapy PET-CT. Five (9.6%) patients had a DS of 4 after completion of therapy and were treated more aggressively with more cycles of chemotherapy or a change in the regimen and/or field radiotherapy. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. 6, 8. https://doi.org/10.1186/s40658-019-0244-0 (2019). To further verify the reliability of the results, the number of features was reduced using different techniques. The most common subtype, diffuse large B-cell lymphoma, has a 40% lifetime relapse rate.37 Lifetime relapse in Hodgkin lymphoma occurs in 10% to 15% of patients with early stage disease and 40% of patients with advanced stage disease.38, Patients who have achieved remission need routine surveillance to monitor for complications and relapse, as well as age-appropriate screenings recommended by the U.S. Preventive Services Task Force.39 Complications of lymphoma treatment include secondary malignancies (e.g., breast, lung, skin, colon), cardiac disease, infertility, and endocrine, neurologic, and psychiatric dysfunctions. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkins lymphoma: An analysis from the St Jude Lifetime Cohort Study. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkins disease: Report from the Late Effects Study Group. Methods 188, 105111. Their interim, end of treatment, and follow-up PET scans were retrospectively visually analyzed and assigned DS by three nuclear medicine physicians. ; Amthauer, H.; Ruf, J.; Misch, D.; Schnberger, S.; Kobe, C.; Denecke, T.; Stver, B.; Hautzel, H.; et al. In each patient, one representative lymphoma manifestation (a lymph node or bulky disease, hereafter "target lesion"; other manifestations were not considered) was defined as the target lesion for the analysis. Mol. After five years of being cancer free, the patient can be transitioned to a primary care physician.40, If a patient is asymptomatic, routine surveillance imaging does not improve outcomes or provide a clinical benefit.40,41 Surveillance imaging should be used in patients who have reported symptoms or who are at high risk of relapse in a place that would not be easily examined, and who would be candidates for treatment. WebMy Research and Language Selection Sign into My Research Create My Research Account English; Help and support. The relevant cutoff was between DS3 and DS4 and defined by a qPET value of 1.323: lesions equal or above were classified as DS4-positive, lesions below as DS4-negative. https://qiicr.org/tool/PETIndiC/ (2018). Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A. Leuk. Sci. 2013;54(11):2531-2533. Hello I want to change document wide default font. ; Bartelink, H.; van Leeuwen, F.E. State after first-line standardized chemotherapy was based on the 5-Point Deauville Score. WebInterim PET/CT scan was performed after 23 cycles of therapy, and the response was assessed using the Deauville 5-point scales (5-PS) and a semi-quantitative assessment using the SUVmax reduction rate (SUVmax). 10 Results showed superior results for patients who were PET negative. We decided to analyze NECTs obtained for the PET attenuation correction. DS gives the threshold for adequate or inadequate response to be adapted according to the clinical context or research question. ; Krasin, M.J.; Kogos, P.G. CAS Unauthorized use of these marks is strictly prohibited. investigated a lymph node/aorta density ratio in patients with non-small cell lung cancer undergoing preoperative 18F-FDG-PET/CT, pointing out a correlation between lymph node metastases and lymph node density40. Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. A median activity of 250MBq 18F-FDG (interquartile range (IQR), 233262MBq) was administered intravenously. For example, Ganeshan et al. Save my name, email, and website in this browser for the next time I comment. 2021;62(8):1102-1111. doi: 10.11406/rinketsu.62.1102. Shahzadi, I. et al. PET Clin. Shao et al. positive feedback from the reviewers. PubMed Central The https:// ensures that you are connecting to the Linch DC, Winfield D, Goldstone AH, et al. Interobserver variability was calculated using weighted Kappa and presented with 95% confidence interval. permission provided that the original article is clearly cited. Phys. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Dr. Julian Rogasch is participant in the BIH-Charit Digital Clinician Scientist Program funded by the Charit Universittsmedizin Berlin, the Berlin Institute of Health, and the German Research Foundation (DFG). Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT. Kluge, R.; Kurch, L.; Georgi, T.; Metzger, M. Current role of FDG-PET in pediatric Hodgkins lymphoma. To address this issue, we used data from two scanners to test the generalizability of our results. ; writingreview and editing, F.I., M.G., L.F.; supervision, S.P., D.C., E.N. Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with hodgkin lymphoma. Research reported in this article was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 5U54GM104942-03. ; Kluge, R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Repeatability and reproducibility study of radiomic features on a phantom and human cohort. Flechsig, P. et al. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. https://doi.org/10.1007/s11307-017-1155-x (2018). Kursa, M. B. Praznik: High performance information-based feature selection. PubMed Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). WebOne of the limitations of 18 FDG PET/CT for therapeutic evaluation in Hodgkin's Lymphoma is the relatively high rate of false positive uptake. Straus DJ, Dugosz-Danecka M, Connors JM, Alekseev S, Ills , Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Lancet Haematol. The site is secure. Oncol. J.Nucl. This feature could be easily applied on NECT images to estimate relevant metabolic activity when a PET scan is unavailable. Hodgkin lymphoma is treated with combined chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), Stanford V (a chemotherapy regimen consisting of mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone), or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) with radiotherapy. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK. Shrout, P. E. & Fleiss, J. L. Intraclass correlations: Uses in assessing rater reliability. Leuk. Flechsig, P. et al. Lancet. Unsupported neutrophil count <1.0 x 109/l and platelet count <100 x 109/l unless due to bone marrow infiltration by Hodgkin lymphoma demonstrated by trephine biopsy; Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), bendamustine, and lenalidomide. Purpose: Copyright 2020 by the American Academy of Family Physicians. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: A systematic review. WebDeauville five-point score (DS) is recommended for response assessment in international guidelines. Journal of Personalized Medicine 13, no. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Sci. SUV max reduction (SUV max) and tumor/liver ratio (TLr) are promising tools for response assessment in lymphoma.We determined the optimal cutoff values for SUV max and TLr and J. Pers. Exp Hematol Oncol. ; validation, C.F.,H.A. Editors Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. ; Kuyumcu, S.; Kebudi, R.; Sanli, Y.; Karakas, Z.; Cakir, F.B. Rep. 11, 2055. https://doi.org/10.1038/s41598-021-81526-8 (2021). Blood. Revelle, W. psych: Procedures for Psychological, Psychometric, and Personality Research. Applied logistic regression. PET/CT (b,c) show this manifestation to be FDG-positive. Aide, N.; Lasnon, C.; Veit-Haibach, P.; Sera, T.; Sattler, B.; Boellaard, R. EANM/EARL harmonization strategies in PET quantification: From daily practice to multicentre oncological studies.
Best Character Dining At Disney World For Toddlers,
Hisun Sector 750 Problems,
Articles D
